TransEnterix (TRXC) Reports 25M Share Registered Direct Offering at $1.25/Sh

TransEnterix, Inc. (NYSE: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered into securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering of 25,000,000 shares of its common stock at a purchase price of $1.25 per share for gross proceeds of $31.25 million. The offering is expected to close on or about January 14, 2021, subject to satisfaction of customary closing conditions.

TransEnterix intends to use the net proceeds from the registered direct offering to for general corporate purposes, including working capital.

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
• Largo Resources Ltd. (LGO) PT Lowered to $2.40 at H.C. Wainwright
• H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ)